Galmed Receives European Patent for Aramchol & Resmetirom Combo

Galmed Receives European Patent for Aramchol & Resmetirom Combo

By, Admin 19 March 2024

Galmed Pharma receives European patent for combination of Aramchol with Resmetirom to treat NASH and liver fibrosis

Overview

Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced the grant of a European patent related to the use of a combination of Aramchol and Resmetirom (MGL-3196, Rezdiffra) for the treatment of NASH/MASH and liver fibrosis.

Approved Countries

  • The patent was granted in France, Germany, Italy, the Netherlands and the United Kingdom and the approval of the patent in the United States and other countries is pending. 
  • With this latest patent, Galmed is strengthening and extending the patent protection of its lead compound, Aramchol, until September 2039.

Phase 3 NASH Study Results

Previously, Galmed reported results from the Open-Label part of its Phase 3 NASH study, which demonstrated that treatment with Aramchol 300mg BID resulted in a high rate of subjects with fibrosis improvement.

Combination Therapy

  • Galmed has long believed that the optimum treatment for NASH/MASH will be combination therapy. Aramchol has been shown to down-regulate the expression and activity of stearoyl-CoA desaturase-1 (SCD1) in hepatic stellate cells, resulting in a direct effect on fibrogenesis. 
  • Aramchol's unique mechanism of action differs from others in its competitive landscape, positioning it to work as a potent anti-fibrotic compound alongside effective treatments in both approved and pre-approval stages. 

Words from CEO: Galmed Pharmaceuticals

Allen Baharaff, CEO and president of Galmed Pharmaceuticals mentioned that ""this new patent for the combination of Aramchol and Resmetirom reflects the same spirit of earlier patents which were granted to Galmed by the United States Patent and Trademark Office (USPTO) for the treatment for hepatic fibrosis."" Baharaff continued ""It is clear today that NASH is a chronic condition with multiple liver pathologies. Among all pathologies, excessive liver fat, high glycaemic index and fibrosis are major treatment challenges. By combining Aramchol and Resmetirom, two distinct and selective compounds with complementary mechanisms, we believe this will provide a perfect treatment for NASH."

About Galmed Pharmaceuticals

  • Galmed Pharmaceuticals Ltd., is a clinical stage biopharmaceutical company focused on the development of Aramchol for liver and fibro-inflammatory diseases. 
  • The company have focused almost exclusively on developing Aramchol for the treatment of NASH and are currently developing Aramchol for PSC and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of liver disease.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!